Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1998 Jun;42(6):1412-6.
doi: 10.1128/AAC.42.6.1412.

Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations

E M Johnson  1 , J O Ojwang, A Szekely, T L Wallace, D W Warnock
Affiliations
Comparative Study

Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations

E M Johnson et al. Antimicrob Agents Chemother. 1998 Jun.

Abstract

The in vitro activity of a multilamellar liposomal formulation of nystatin (Nyotran) was compared with those of free nystatin and four pharmaceutical preparations of amphotericin B. MICs for 200 isolates of two Aspergillus spp., seven Candida spp., and Cryptococcus neoformans were determined by a broth microdilution adaptation of the method recommended by the National Committee for Clinical Laboratory Standards. Minimum lethal concentrations (MLCs) of the six antifungal preparations were also determined. Both nystatin formulations possessed fungistatic and fungicidal activities against the 10 species tested. Liposomal nystatin appeared to be as active as free nystatin, with MICs and MLCs that were similar to, or lower than, those of the latter. Neither formulation of nystatin was as active as amphotericin B deoxycholate (Fungizone) or amphotericin B lipid complex (Abelcet), but both were more effective than liposomal amphotericin B (AmBisome). Our results suggest that further evaluation of liposomal nystatin is justified.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Anaissie E, Paetznick V, Proffitt R, Adler-Moore J, Bodey G P. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis. 1991;10:665–668. - PubMed
    1. Boutati E I, Maltezou H C, Lopez-Berestein G, Vartivarian S E, Anaissie E J. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C: American Society for Microbiology; 1995. Phase I study of maximum tolerated dose of intravenous liposomal nystatin (L-NYST) for the treatment of refractory febrile neutropenia (RFN) in patients with hematological malignancies, abstr. LM22; p. 330.
    1. Broughton M C, Bard M, Lees N D. Polyene resistance in ergosterol producing strains of Candida albicans. Mycoses. 1991;34:75–83. - PubMed
    1. Brown R, Hazen E L, Mason A. Effect of fungicidin (nystatin) in mice injected with lethal mixtures of aureomycin and Candida albicans. Science. 1953;117:609–610. - PubMed
    1. Campbell C C, O’Dell E T, Hill G B. Therapeutic activity of nystatin in experimental systemic mycotic infections. Antibiot Annu. 1955;1955:858–862.

Publication types

LinkOut - more resources